Controlled release pharmaceutical formulations of nitazoxanide
    1.
    发明申请
    Controlled release pharmaceutical formulations of nitazoxanide 有权
    硝唑尼特的控释药物制剂

    公开(公告)号:US20100209505A1

    公开(公告)日:2010-08-19

    申请号:US12656704

    申请日:2010-02-12

    摘要: Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

    摘要翻译: 提供硝唑尼特或硝唑尼特类似物的固体剂量制剂,其包含受控释放部分和速释部分。 药物组合物通常为双层固体口服剂型的形式,其包含(a)在控制释放制剂中包含第一量的硝唑尼特或其类似物的第一层; 和(b)在立即释放制剂中包含第二量的硝唑尼特或其类似物的第二层。 还提供了用于治疗丙型肝炎的方法。

    Viral hepatitis treatment
    2.
    发明申请
    Viral hepatitis treatment 有权
    病毒性肝炎治疗

    公开(公告)号:US20070167504A1

    公开(公告)日:2007-07-19

    申请号:US11651672

    申请日:2007-01-09

    IPC分类号: A61K31/426 A61K38/21

    摘要: The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions.

    摘要翻译: 本公开涉及治疗病毒性肝炎的方法,可用于治疗病毒性肝炎的化合物和包含这些化合物的药物组合物。 在一个实施方案中,提供了包含硝唑尼特,替佐昔奈或其衍生物和/或其混合物的药物组合物,以及使用这些组合物治疗丙型肝炎的方法。

    Method for treatment of trematodes with pharmaceutical compositions of
tizoxanide and nitazoxanide
    3.
    发明授权
    Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide 失效
    用噻唑尼特和硝唑尼特的药物组合物治疗吸虫的方法

    公开(公告)号:US5856348A

    公开(公告)日:1999-01-05

    申请号:US887810

    申请日:1997-07-03

    摘要: Methods for treatment of a parasitic infection of a trematode selected from the group consisting of Schistosoma such as Schistosoma mansoni, Schistosoma haematobium, Schistosoma mekongi, Schistosoma japonicum, and Schistosoma intercalatum, Fasciola such as Fasciola hepatica and Fasciola gigantica, Fasciolopsis buski, Dicrocoelium dendriticun, Heterophyes heterophyes, and Metagonimus yokogawa, the methods comprising administration of a pharmaceutical composition containing as active agent at least one compound selected the group consisting of a compound of formula I: ##STR1## and a compound of formula II: ##STR2##

    摘要翻译: 用于治疗寄生虫感染的方法,其选自血吸虫例如血吸虫血吸虫,血吸虫,日本血吸虫,日本血吸虫,血吸虫,Fasciola hepatica和Fasciola gigantica,Fasciolopsis buski,Dicrocoelium dendriticun, 异嗜异嗜性嗜异性嗜异性嗜异性嗜异性嗜异性嗜血杆菌和横氏马鞭霉的方法,包括施用含有作为活性剂的药物组合物的方法,所述药物组合物含有至少一种选自式I化合物:式(I)化合物和式II化合物的化合物: (二)

    Viral hepatitis treatment
    4.
    发明授权
    Viral hepatitis treatment 有权
    病毒性肝炎治疗

    公开(公告)号:US08633230B2

    公开(公告)日:2014-01-21

    申请号:US11651672

    申请日:2007-01-09

    摘要: The present disclosure relates to methods for treating viral hepatitis, compounds useful in the treatment of viral hepatitis, and pharmaceutical compositions comprising such compounds. In one embodiment, pharmaceutical compositions comprising nitazoxanide, tizoxanide, or derivatives and/or mixtures thereof are provided, as well as methods of treating hepatitis C using such compositions.

    摘要翻译: 本公开涉及治疗病毒性肝炎的方法,可用于治疗病毒性肝炎的化合物和包含这些化合物的药物组合物。 在一个实施方案中,提供了包含硝唑尼特,替佐昔奈或其衍生物和/或其混合物的药物组合物,以及使用这些组合物治疗丙型肝炎的方法。

    Halogenated benzamide derivatives
    6.
    发明授权
    Halogenated benzamide derivatives 有权
    卤代苯甲酰胺衍生物

    公开(公告)号:US07550493B2

    公开(公告)日:2009-06-23

    申请号:US11865541

    申请日:2007-10-01

    IPC分类号: A61K31/426 C07D277/20

    CPC分类号: C07D277/46

    摘要: A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds and where at least two of R2-R6 are not hydrogen and where at least one of R2-R6 are hydroxy or acyloxy.

    摘要翻译: 根据式(III),其中R 1是卤素原子,且R 2 -R 6独立地是氢,羟基,C 1 -C 4烷基, - (C 1 -C 4)烷基, - 卤代苯甲酰胺衍生物,其特征在于对病毒病原体具有更大的特异性并且更少破坏有益的肠道微生物群落) C 1 -C 4烷氧基,酰氧基,硝基,卤素,-C(O)R 7,其中R 7是-C 1 -C 4烷基,或这些化合物的芳香族包括盐和水合物,其中至少两个R 2 -R 6不是氢, R 2 -R 6中的至少一个是羟基或酰氧基。

    Halogenated benzamide derivatives
    7.
    发明授权
    Halogenated benzamide derivatives 有权
    卤代苯甲酰胺衍生物

    公开(公告)号:US07285567B2

    公开(公告)日:2007-10-23

    申请号:US11221256

    申请日:2005-09-06

    IPC分类号: A61K31/426 C07D277/20

    CPC分类号: C07D277/46

    摘要: A halogenated benzamide derivative characterized by greater specificity for viral pathogens and less disruptive to beneficial gut microflora, according to formula (III): in which R1 is a halogen atom, and R2-R6 are independently hydrogen, hydroxyl, C1-C4 alkyl, —C1-C4 alkoxy, acyloxy, nitro, halogen, —C(O)R7 where R7 is —C1-C4 alkyl, or, aromatic including salts and hydrates of these compounds.

    摘要翻译: 一种卤化苯甲酰胺衍生物,其特征在于对病毒病原体具有更高的特异性,并且对根据式(III)的有益的肠道微生物群落的破坏性较小:其中R 1是卤素原子,R 2, N 1 -R 6独立地是氢,羟基,C 1 -C 4烷基,-C 1 - C 4烷氧基,酰氧基,硝基,卤素,-C(O)R 7,其中R 7是-C 1 -C 4烷基,或这些化合物的芳族包括盐和水合物 。

    Antiviral composition
    8.
    发明授权
    Antiviral composition 失效
    抗病毒组成

    公开(公告)号:US5886013A

    公开(公告)日:1999-03-23

    申请号:US847130

    申请日:1997-05-01

    IPC分类号: A01N43/78 A61K31/425

    摘要: The present invention relates to a pharmaceutical composition containing a compound of formula I ##STR1## with one of the symbols R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 representing OH, whereas the remaining symbols represent H as antiviral agent.

    摘要翻译: 本发明涉及包含式I化合物的药物组合物,其中符号R1,R2,R3,R4和R5之一代表OH,而其余符号代表H作为抗病毒剂。

    Phenanthrene methanol compounds useful as antimalarial agents
    9.
    发明授权
    Phenanthrene methanol compounds useful as antimalarial agents 失效
    菲甲醇化合物可用作抗疟剂

    公开(公告)号:US5250734A

    公开(公告)日:1993-10-05

    申请号:US889407

    申请日:1992-05-28

    IPC分类号: C07C215/30 C07C215/16

    CPC分类号: C07C215/30 C07C2103/26

    摘要: A compound represented by the following formula (I): ##STR1## wherein R is hydrogen, methyl, ethyl, propyl, butyl, phenyl, CH.sub.2 CH(OH)CH.sub.3, CH.sub.2 CH(OH)CH(OH), CH.sub.2 CH.sub.2 CH.sub.2 -phenyl, or a group of the formula (CH.sub.2).sub.x -Ar, where x is 0 to 4 and Ar is a 6-membered ring from phenyl, pyridyl, cyclohexyl, or pyranyl, each of which may be substituted with a hydrophilic group(s), andX can be Cl, tartrate, oxalate, or quinate.

    摘要翻译: 由下式(I)表示的化合物:其中R是氢,甲基,乙基,丙基,丁基,苯基,CH 2 CH(OH)CH 3,CH 2 CH(OH)CH(OH),CH 2 CH 2 CH 2 - ,或式(CH2)x-Ar的基团,其中x为0至4,Ar为来自苯基,吡啶基,环己基或吡喃基的6-元环,其各自可以被亲水基团取代 ),X可以是Cl,酒石酸盐,草酸盐或季铵盐。